Global Extended Release Drug 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12242314

Publication Date:

December 18, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Extended Release Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Extended Release Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Extended Release Drug market. Extended Release Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Extended Release Drug. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Extended Release Drug market.
Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target.听Extended release drugs听is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Extended Release Drug market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Extended Release Drug market. It may include historical data, market segmentation by Type (e.g., Sustained Release Drug, Controlled Release Drug), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Extended Release Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Extended Release Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Extended Release Drug industry. This include advancements in Extended Release Drug technology, Extended Release Drug new entrants, Extended Release Drug new investment, and other innovations that are shaping the future of Extended Release Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Extended Release Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Extended Release Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Extended Release Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Extended Release Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Extended Release Drug market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Extended Release Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Extended Release Drug market.
麻豆原创 Segmentation:
Extended Release Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Sustained Release Drug
Controlled Release Drug
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Extended Release Drug 麻豆原创 Size 2019-2030
2.1.2 Extended Release Drug 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Extended Release Drug Segment by Type
2.2.1 Sustained Release Drug
2.2.2 Controlled Release Drug
2.3 Extended Release Drug 麻豆原创 Size by Type
2.3.1 Extended Release Drug 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Extended Release Drug 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Extended Release Drug Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Extended Release Drug 麻豆原创 Size by Application
2.5.1 Extended Release Drug 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Extended Release Drug 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Extended Release Drug 麻豆原创 Size by Player
3.1 Extended Release Drug 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Extended Release Drug Revenue by Players (2019-2024)
3.1.2 Global Extended Release Drug Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Extended Release Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Extended Release Drug by Regions
4.1 Extended Release Drug 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Extended Release Drug 麻豆原创 Size Growth (2019-2024)
4.3 APAC Extended Release Drug 麻豆原创 Size Growth (2019-2024)
4.4 Europe Extended Release Drug 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Extended Release Drug 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Extended Release Drug 麻豆原创 Size by Country (2019-2024)
5.2 Americas Extended Release Drug 麻豆原创 Size by Type (2019-2024)
5.3 Americas Extended Release Drug 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Extended Release Drug 麻豆原创 Size by Region (2019-2024)
6.2 APAC Extended Release Drug 麻豆原创 Size by Type (2019-2024)
6.3 APAC Extended Release Drug 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Extended Release Drug by Country (2019-2024)
7.2 Europe Extended Release Drug 麻豆原创 Size by Type (2019-2024)
7.3 Europe Extended Release Drug 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Extended Release Drug by Region (2019-2024)
8.2 Middle East & Africa Extended Release Drug 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Extended Release Drug 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Extended Release Drug 麻豆原创 Forecast
10.1 Global Extended Release Drug Forecast by Regions (2025-2030)
10.1.1 Global Extended Release Drug Forecast by Regions (2025-2030)
10.1.2 Americas Extended Release Drug Forecast
10.1.3 APAC Extended Release Drug Forecast
10.1.4 Europe Extended Release Drug Forecast
10.1.5 Middle East & Africa Extended Release Drug Forecast
10.2 Americas Extended Release Drug Forecast by Country (2025-2030)
10.2.1 United States Extended Release Drug 麻豆原创 Forecast
10.2.2 Canada Extended Release Drug 麻豆原创 Forecast
10.2.3 Mexico Extended Release Drug 麻豆原创 Forecast
10.2.4 Brazil Extended Release Drug 麻豆原创 Forecast
10.3 APAC Extended Release Drug Forecast by Region (2025-2030)
10.3.1 China Extended Release Drug 麻豆原创 Forecast
10.3.2 Japan Extended Release Drug 麻豆原创 Forecast
10.3.3 Korea Extended Release Drug 麻豆原创 Forecast
10.3.4 Southeast Asia Extended Release Drug 麻豆原创 Forecast
10.3.5 India Extended Release Drug 麻豆原创 Forecast
10.3.6 Australia Extended Release Drug 麻豆原创 Forecast
10.4 Europe Extended Release Drug Forecast by Country (2025-2030)
10.4.1 Germany Extended Release Drug 麻豆原创 Forecast
10.4.2 France Extended Release Drug 麻豆原创 Forecast
10.4.3 UK Extended Release Drug 麻豆原创 Forecast
10.4.4 Italy Extended Release Drug 麻豆原创 Forecast
10.4.5 Russia Extended Release Drug 麻豆原创 Forecast
10.5 Middle East & Africa Extended Release Drug Forecast by Region (2025-2030)
10.5.1 Egypt Extended Release Drug 麻豆原创 Forecast
10.5.2 South Africa Extended Release Drug 麻豆原创 Forecast
10.5.3 Israel Extended Release Drug 麻豆原创 Forecast
10.5.4 Turkey Extended Release Drug 麻豆原创 Forecast
10.5.5 GCC Countries Extended Release Drug 麻豆原创 Forecast
10.6 Global Extended Release Drug Forecast by Type (2025-2030)
10.7 Global Extended Release Drug Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Extended Release Drug Product Offered
11.1.3 Pfizer Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 Mallinckrodt
11.2.1 Mallinckrodt Company Information
11.2.2 Mallinckrodt Extended Release Drug Product Offered
11.2.3 Mallinckrodt Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Mallinckrodt Main Business Overview
11.2.5 Mallinckrodt Latest Developments
11.3 Teva
11.3.1 Teva Company Information
11.3.2 Teva Extended Release Drug Product Offered
11.3.3 Teva Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Teva Main Business Overview
11.3.5 Teva Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Extended Release Drug Product Offered
11.4.3 Johnson & Johnson Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
11.5 Endo Pharmaceuticals
11.5.1 Endo Pharmaceuticals Company Information
11.5.2 Endo Pharmaceuticals Extended Release Drug Product Offered
11.5.3 Endo Pharmaceuticals Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Endo Pharmaceuticals Main Business Overview
11.5.5 Endo Pharmaceuticals Latest Developments
11.6 Purdue Pharma
11.6.1 Purdue Pharma Company Information
11.6.2 Purdue Pharma Extended Release Drug Product Offered
11.6.3 Purdue Pharma Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Purdue Pharma Main Business Overview
11.6.5 Purdue Pharma Latest Developments
11.7 Mylan
11.7.1 Mylan Company Information
11.7.2 Mylan Extended Release Drug Product Offered
11.7.3 Mylan Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Mylan Main Business Overview
11.7.5 Mylan Latest Developments
11.8 Hisamitsu Pharmaceutical
11.8.1 Hisamitsu Pharmaceutical Company Information
11.8.2 Hisamitsu Pharmaceutical Extended Release Drug Product Offered
11.8.3 Hisamitsu Pharmaceutical Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Hisamitsu Pharmaceutical Main Business Overview
11.8.5 Hisamitsu Pharmaceutical Latest Developments
11.9 Sun Pharmaceutical Industries
11.9.1 Sun Pharmaceutical Industries Company Information
11.9.2 Sun Pharmaceutical Industries Extended Release Drug Product Offered
11.9.3 Sun Pharmaceutical Industries Extended Release Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Sun Pharmaceutical Industries Main Business Overview
11.9.5 Sun Pharmaceutical Industries Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.